Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2025.316 | Can biologic DMARD use retard syndesmophytes and facet joint arthritis progression and resolve axial inflammatory in psoriatic arthritis? A prospective follow up study using low-dose computed tomography and magnetic resonance imaging | Prof. TAM Lai Shan |
| 2024.182 | Causal machine learning models for prediction of serious infection events in inflammatory arthritis: a population-based study |
Prof. TAM Lai Shan Lai Shan TAM |
| 2024.193 | Lowest Efficacious Dose in Psoriatic Arthritis (LED PsA): A Multicentre Non-inferiority Randomized Open-Label Controlled Trial Assessing b/tsDMARDs Spacing | Prof. TAM Lai Shan |
| 2026.341 | A Phase 1, open-label, dose-escalation study (ELEVATE-1) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a CD19/CD20 T-cell engager in participants with B-cell driven autoimmune rheumatic diseases (ARD) | Prof. Tam Lai Shan |
| 2026.229 | Prospective MRI and HR-pQCT Study of Subclinical Musculoskeletal Involvement in Psoriasis with Arthralgia and Progression to Psoriatic Arthritis | Prof. Tam Lai Shan |
| 2026.275 | Investigating the presence of anti-citrullinated SR-A peptide antibodies as a novel biomarker for RA | Prof. TAM Lai Shan |
| 2026.407 | Incident comorbid cardiovascular disease in patients with rheumatoid arthritis | Prof. Tam Lai Shan |
| 2026.338 | Treat-to-target aiming at DORIS remission and progression of subclinical atherosclerosis in systemic lupus erythematosus: a 2-year prospective cohort using high-resolution carotid ultrasound |
Prof. TAM Lai Shan 譚麗珊 |
| 2026.344 | Therapeutic strategy and remission of rheumatoid arthritis in the Asia-Pacific region - A multicenter real-world study | Prof. Tam Lai Shan |
| 2021.187 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Dapirolizumab pegol in Study Participants with Moderately to Severely Active Systemic Lupus Erythematosus |
Prof. TAM Lai Shan 譚麗珊 教授 |
| 2021.315 | Axial involvement in patients with Psoriatic Arthritis in Hong Kong – a cross-sectional pilot study |
Prof. TAM Lai Shan 譚麗珊 |
| 2021.460 | Profiling of Serum Protein Biomarkers in Psoriatic Arthritis–Associated Disease Activity Assessment and Bone Damage |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.704 | Bone Erosion Volume Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) as predictor of disability in patients with rheumatoid arthritis | Prof. TAM Lai Shan |
| 2021.568 | A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.516 | CUHK Rheumatology Research Centre Imaging Database of Rheumatic Diseases |
Prof. TAM Lai Shan 譚麗珊 |
| 2023.355 | Sex- And Gender-based analysis of the Effectiveness of advanced therapies in Psoriatic Arthritis | Prof. TAM Lai Shan |
| 2022.151 | Osteosarcopenia Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) and fracture risk in non-osteoporotic patients with immune-mediated inflammatory disease |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.519 | Cardiovascular events in axial spondyloarthritis |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.530 | 5-Year Cardiovascular Event Risk in Early Rheumatoid Arthritis Patients who received Treat-to-Target Management: a population-based cohort study |
Prof. TAM Lai Shan 譚麗珊 |
| 2021.401 | A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Anifrolumab in Asian Participants with Active Systemic Lupus Erythematosus |
Prof. TAM Lai Shan 譚麗珊 |
| 2021.343 | AXIAL INVOLVEMENT IN PSORIATIC ARTHRITIS COHORT (AXIS) a joint ASAS-GRAPPA project |
Prof. TAM Lai Shan 譚麗珊 |
| 2023.051 | Discovering new post-translational modification patterns for the early diagnosis of rheumatoid arthritis | Prof. TAM Lai Shan |
| 2020.617 | Subclinical atherosclerosis in axial spondyloarthritis- a cross-sectional study |
Prof. TAM Lai Shan 譚麗珊 |
| 2022.686 | Bone Erosion Volume Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) as predictor of disability in patients with psoriatic arthritis | Prof. TAM Lai Shan |
| 2023.317 | Early identification of axial psoriatic arthritis among patients with psoriasis: a screening study using low-dose computed tomography | Prof. TAM Lai Shan |
| 2023.127 | Machine learning models to quantify and predict radiographic joint damage in rheumatoid arthritis |
Prof. TAM Lai Shan Lai Shan TAM |
| 2023.189 | Survey of cardiovascular disease Risk Factors in Psoriatic Arthritis | Prof. TAM Lai Shan |
| 2023.306 | Low-dose computed tomography for the detection of structural changes in axial psoriatic arthritis | Prof. TAM Lai Shan |
| 2021.706 | Effect of Achieving Minimal Disease on the Progression of Subclinical Coronary Atherosclerosis: A Citywide Prospective Cohort Study in Psoriatic Arthritis |
Prof. TAM Lai Shan 譚麗珊 |
| 2023.181 | Anti-inflammatory mechanisms of immune-adipose-related Meteorin-like protein (METRNL) in Systemic Lupus Erythematosus | Dr. TAM Lai Shan |
| 2011.050 | A Randomized, Double-Blind Phase 2b Study to Evaluate the Efficacy, Safety, and Tolerability of A-623 Administration in Subjects with Systemic Lupus Erythematosus | Professor Tam Lai-Shan |
| 2011.562 | An Open-Label Long-term Safety Extension Trial for Subjects with Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321 (PEARL-SC) | Professor Tam Lai-Shan |
| 2011.276 | Ankylosing spondylitis vascular study | Prof. TAM Lai-Shan |
| 2011.558 | RAGE: a new therapeutic target and biomarker of rheumatoid arthritis | Professor Tam Lai-Shan |
| 2012.082 | Periatricular and generalized bone loss in psoriatic arthritis | Prof. Tam Lai-Shan |
| 2011.209 | Assessment of PROMIS Fatigue Bank with SLE-specfic items for use in an Asian SLE population in Hong Kong and Singapore | Prof. TAM Lai-Shan |
| 2021.663 | A retrospective study to evaluate the pulmonologist-pharmacist care model at the pharmacist respiratory clinic in an acute teaching hospital in Hong Kong. | Ms. TAM Lyanna Lik Yan |
| 2025.368 | Retention rate of adalimumab bio-original and biosimilars in rheumatic diseases: a real-world study from the Hong Kong Biologics Registry |
Dr. TAM Lydia Ho Pui 譚皓珮 |
| 2025.218 | Clinical characteristics and outcomes of patients with Adult-Onset Still’s Disease (AOSD) in Hong Kong | Dr. TAM Lydia Ho Pui |
| 2024.179 | Leadless pacemaker implantation positions and its relationship with procedure efficacy and complication |
Dr. TAM Mark Tsz Kin 譚子健 |
| 2024.028 | Coronary study in patients undergoing AF ablation |
Dr. TAM Mark Tsz Kin 譚子健 |
| 2024.350 | Catheter Ablation in Atrial Fibrillation Patients with Heart Failure with Preserved Ejection Fraction: an International, Prospective, Multi-center, Randomized Controlled study |
Prof. TAM Mark Tsz Kin 譚子健 |
| 2024.662 | A Stylet-Driven ICD Lead Intended for Conduction System Pacing IDE Study |
Prof. TAM Mark Tsz Kin 譚子健 |
| 2023.685 | A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation versus Anti-Arrhythmic Drug Therapy as a First Line Treatment for Persistent Atrial Fibrillation (AVANT GUARD) |
Dr. TAM Mark Tsz Kin 譚子健 |
| 2025.045 | Cardiovascular physiological signal recording project |
Prof. TAM Mark Tsz Kin 譚子健 |
| 2024.184 | Smartwatch paroxysmal arrhythmia detection compared with Holter - a multicenter controlled trial |
Dr. TAM Mark Tsz Kin 譚子健 |
| 2018.371 | Tricuspid regurgitation after cardiac implantable electronic device implantation | Dr. TAM Mark Tsz Kin |
| 2022.456 | Atrial fibrillation ablation registry |
Dr. TAM Mark Tsz Kin 譚子健 |
| 2023.406 | Drug - drug interaction (DDI) of direct oral anticoagulants database research |
Dr. TAM Mark Tsz Kin 譚子健 |
| 2022.505 | Artificial intelligence to improve procedure safety of atrioventricular nodal reentrant tachycardia ablation – a retrospective feasibility study | Dr. TAM Mark Tsz Kin |
Page 219 of 289.